Answers are grounded in this paper and cite their sources.
As reported at the IVth Joint Meeting of LWPES/ESPE, an International Task Force (ITF) of over 50 investigators world-wide was formed to analyze the final height attainment in normal children with short stature who have been treated with GH for at least three years.Only small numbers of children worldwide met the entry criteria and have reached final or“near-final” height following GH treatment. The ITF study group consisted of 60 males and 39 females with idiopathic short stature. The normal short boys and girls exceeded their mean predicted height by 3.0cm and 2.6cm respectively, but they failed to reach mid-parental target height by 5.6cm and 6.8cm respectively. The first two years of GH therapy were associated with increased growth velocity and an acceleration in bone age. Since the majority of patients had received GH for over four years, the net improvement in mean height velocity produced by GH was < 1cm/year. There was no significant dose-response relationship. Only in 4% was the result considered“very good”, 31% considered the outcome“good”, and 40% considered there was no benefit; 24% did not comment. Thus it seem unlikely that GH will significantly increase final height in normal short children.Based upon current knowledge and experience, the use of GH for the treatment of the normal child with short stature outside of carefully controlled clinical trials, especially by physicians not experienced in the conduct of such trials, cannot be recommended as standard treatment at present.
No takes yet. Share an insight, caveat, or question.
H. Guyda (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: